Introduction
Periprosthetic infection is estimated to occur in 1-2% of all prosthetic surgery patients.
The paradigm for managing this challenging condition lies in a thorough understanding
of the role biofilm plays in the process. In 1983, Dr. Insall and colleagues first
published how they successfully resolved a prosthetic knee infection with a two-stage
revision and replacement.[1] Later, the importance of biofilm would be discovered, and the reason why isolated
antibiotic therapy is ineffective in the management of this entity.[2]
The development of biofilms on prosthetic surfaces is a process favored by the presence
of the implant, which acts as an ideal substrate for bacterial adhesion. These organized
bacterial communities hinder the effective penetration of antimicrobials, especially
in the deeper layers.[3] As a result, in advanced cases, the dismantling of the prosthetic components is
necessary, which increases both the patient's morbidity and mortality as well as healthcare
costs, with an estimated economic impact of between $40,000 and $160,000 per case.[4] In fact, it has been estimated that the cost of a revision arthroplasty due to infection
can be up to four times higher than that of a primary arthroplasty and twice that
of an aseptic revision, representing a significant burden on healthcare systems.
Since biofilm maturation directly influences therapeutic strategy, determining the
timing of its formation is crucial. Its degree of development, along with factors
related to the patient and previous surgery, determines the management of infection
in joint prostheses.[5] Traditionally, infections have been classified as acute or chronic according to
their duration; however, this distinction is merely academic, since symptoms may overlap,
and the duration of the infection varies ([Table 1]).
Table 1
|
Characteristics
|
Acute Prosthetic Infection (Immature Biofilm)
|
Chronic Prosthetic Infection (Mature Biofilm)
|
|
Pathogeny
|
<4 weeks after surgery
|
≥4 weeks after surgery
|
|
Clinical features
|
Acute pain, fever, red and swollen joint, prolonged postoperative drainage
|
Chronic pain, prosthetic loosening, fistulous tract
|
|
Typical microorganisms
|
High virulence: S. aureus, gram-negative (E. coli, Klebsiella)
|
Low virulence: coagulase-negative staphylococci, C. acnes
|
This article addresses the critical importance of a protocolized approach and the
application of early and specific measures in the management of periprosthetic joint
infection. It highlights the need for diligent and coordinated intervention, based
on scientific evidence, to enable the eradication of the infection while preserving
joint function and improving the patient's quality of life after arthroplasty.
Therapeutic Strategies
DAIR
Implant-retaining debridement is an effective tool for managing acute postoperative
infections and acute hematogenous infections in selected patients based on numerous
meta-analyses, with success rates currently around 71%.[6]
[7]
[8]
In those patients with good skin condition, in whom the responsible microorganism
has been identified, without it being polymicrobial, nor resistant to conventional
antimicrobials available in the hospital center and provided that the duration of
the onset of symptoms does not exceed 4-6 weeks[7]
[8] ([Table 2]).
Table 2
|
Required criteria
|
Characteristics
|
|
Duration of symptoms
|
≤ 4-6 weeks.
|
|
Implant not mobilized
|
Stable on imaging tests.
|
|
Microorganism identified
|
Responsive to available antibiotics. Different from fungal, polymicrobial, or enterococcal
infections.
|
|
Good soft tissue condition
|
No abscesses or fistulas.
|
|
Immunocompetent patient
|
No underlying immunosuppressive disease (rheumatic, hematologic, oncologic, etc.)
|
DAIR should not be considered an emergency procedure, since it is advisable to appropriately
select the patient with potentially reversible clinical conditions such as coagulopathy,
nutritional status, hyperglycemia, severe anemia, etc., and to have the modular elements
that need to be replaced.[8] In patients presenting with septic shock whose primary cause is suspected to be
periprosthetic infection, an emergent DAIR may be indicated to reduce the microbial
load, although this is somewhat more debated.
DAIR Failure Prediction Scales
Currently, two scores stand out as useful tools for predicting DAIR failure: the KLIC
score and the CRIME80 score. These have been validated in independent studies and
cited in academic debates, such as the 2019 International Consensus on Prosthetic
Infections, although they are not part of its official recommendations. Despite not
being included in the most recent guidelines on the management of periprosthetic infections,
both offer promising value in risk stratification and selection of patients for the
procedure.[10]
[11]
While the CRIME80 score provides information on the risk of DAIR failure in late acute
infections, the KLIC score is more focused on the prognosis and risk of DAIR failure
in acute postoperative infections. The KLIC score was developed by Tonero et al. and
considers renal failure (K); liver cirrhosis (L); index surgery: primary or revision
(I); and CRP (C), establishing a cutoff point of 4 ([Table 3]). On the other hand, we have the CRIME 80 score, developed by the study group for
implant-associated infections (ESGIAI), within the European Society of Clinical Microbiology
and Infectious Diseases. The variables that define it are: COPD (C); CRP; Rheumatoid
Arthritis (R); index surgery: primary or revision (I); Male (M); Polyethylene change
(E); Age over 80 years, assuming a cut-off point of 3. ([Table 4]).
Table 3
|
Variable
|
Score
|
|
C Chronic obstructive pulmonary disease (COPD)
|
1
|
|
CRP > 150 mg/L
|
1
|
|
R Rheumatoid arthritis
|
3
|
|
I Index surgery (following fracture)
|
3
|
|
M Male
|
1
|
|
E Polyethylene exchange
|
-1
|
|
> 80 years
|
2
|
Table 4
|
Microorganism
|
Initial treatment (IV)
|
Alternatives in case of allergy or resistance
|
Continuation treatment (VO)
|
|
Staphylococcus spp. (MSSA)
|
Cloxacillin or cefazolin
|
Glycopeptides (vancomycin/teicoplanin) or daptomycin
|
Levofloxacin + rifampin or (clindamycin/co-trimoxazole + rifampin) or ceftaroline
(severe cases)
|
|
Staphylococcus spp. (MRSA)
|
Vancomycin (trough target 15-20 mg/L) or daptomycin (8-10 mg/kg)
|
Daptomycin + fosfomycin or ceftaroline
|
Co-trimoxazole or clindamycin + rifampin, or linezolid as monotherapy or daptomycin + fosfomycin
followed by linezolid/co-trimoxazole/clindamycin
|
|
Streptococcus spp.
|
Beta-lactam (penicillin, ampicillin, cephalosporin except for Enterococcus)
|
Vancomycin or teicoplanin
|
Depending on the antibiogram; avoid amoxicillin for Enterococcus spp.
|
|
Enterococcus spp. (E. faecalis)
|
Ampicillin (if sensitive) or vancomycin
|
Teicoplanin or linezolid
|
Oral amoxicillin is not recommended due to high MICs
|
|
Gram negative bacilli (susceptible enterobacteria)
|
Third-generation cephalosporins (ceftriaxone)
|
Ertapenem if ESBL+
|
Fluoroquinolones (levofloxacin) or co-trimoxazole if sensitive
|
|
Pseudomonas aeruginosa
|
Piperacillin-Tazobactam, meropenem, or ceftazidime
|
Colistin or fosfomycin (depending on sensitivity)
|
Fluoroquinolones (ciprofloxacin)
|
Surgical Technique
A wide arthrotomy must first be performed to allow inspection of the entire cavity
and remove both affected material and tissue, leaving no debris that could remain
in any unexposed plane. Next, we will remove both necrotic tissue and tissue suggestive
of infection. It is essential to collect at least five sterile samples during the
surgical procedure, ensuring a complete microbiological analysis that allows identification
of the causative agent and its antibiotic sensitivity profile. We will then perform
a complete 360° synovectomy. Often, due to inadequate exposure of the posterior synovial
tissue, infections persist and debridement with implant retention fails. We will achieve
this in the case of modular knee prostheses, for example, by removing the mobile polyethylene
component.[12] Subsequently, a thorough wash will be necessary, which has been established according
to the latest international consensus guidelines at 9 liters of physiological saline
solution.
Antibiotic Treatment
Treatment of any suspected infection should not begin before the microorganism has
been identified, debridement has been performed, and samples have been collected in
the operating room.
Generally, monotherapy regimen is not usually effective. For methicillin-sensitive
staphylococci, the mainstay of treatment would include levofloxacin and rifampin,
which could be replaced with rifampin plus clindamycin or cotrimoxazole. For methicillin-resistant
staphylococci, vancomycin/daptomycin and rifampin could be used, or rifampin plus
clindamycin/cotrimoxazole/fusidic acid. The addition of rifampin is an important independent
predictor of treatment success due to its significant effect on biofilm resistance.[13] In cases of rifampin resistance or allergy, vancomycin or daptomycin followed by
cotrimoxazole, linezolid, or clindamycin is valid; an alternative is daptomycin plus
fosfomycin followed by linezolid, cotrimoxazole, or clindamycin. For susceptible gram-negative
bacilli, a fluoroquinolone regimen should be initiated. For enterobacteriaceae, ceftriaxone
or ertapenem followed by cotrimoxazole could also be used. For Pseudomonas aeruginosa
infections, alternative treatment could be piperacillin-Tazobactam, meropenem, or
colistin.
Treatment should be initiated with intravenous antibiotics due to their increased
availability in the bloodstream for at least one week. Treatment can then be de-escalated
to oral antibiotic therapy in the following weeks. Most studies recommend a total
of six weeks,[14]
[15] with serial testing of acute-phase reactants during this period, the most important
of which is CRP. [Table 4] summarizes the different antibiotic therapy strategies and alternatives.
DAIR Failure
If the infection has not been eradicated by retaining the fixed components and performing
extensive debridement, it is advisable to consider replacing them. Systematic reviews
describe success rates for the second DAIR like those for the first, so a change in
management strategy should be considered to avoid additional surgical procedures.[16]
[17] A comparison with the indications of the main strategies is detailed in [Table 5].
Table 5
|
Variable
|
Score
|
|
K Chronic kidney failure (Kidney)
|
2
|
|
L Cirrhosis (Liver)
|
1,5
|
|
I Index surgery (revision or after femoral head fracture)
|
1,5
|
|
C Cementation
|
2
|
|
C CRP > 115 mg/L
|
2,5
|
Clinical Cases
To illustrate the application of the CRIME80 and KLIC scores in selecting patients
for DAIR, two real clinical cases of acute periprosthetic infection following total
knee arthroplasty (TKA) are presented.
Case 1
This is a 73-year-old patient with a history of type 2 diabetes mellitus, high blood
pressure, and early chronic kidney disease who underwent total right knee arthroplasty
for severe tricompartmental gonarthrosis. Fourteen days after surgery, she returned
to the clinic for pin removal, at which time the presence of serosanguinous exudate
was observed at the surgical wound, with no signs of gross dehiscence. The patient
was afebrile, without systemic symptoms, although she had joint pain for the past
few days and mild periincisional erythema ([Figure 1]).
Figure 1 Image two weeks after total knee arthroplasty. Periscarring erythema and exudate
from the surgical wound are observed.
Laboratory tests revealed a CRP of 25 mg/L, ESR of 45 mm/h, and leukocytosis of 9,800/µL.
Renal function tests showed a creatinine of 1.1 mg/dL with an estimated glomerular
filtration rate of 65 ml/min. A joint puncture revealed a leukocyte count of 12,500/µL
and a predominance of polymorphonuclear cells (92%), with no microorganisms seen on
Gram stain. X-rays showed no signs of loosening prosthetics, and ultrasound revealed
a joint effusion without organized collections.
Given the time of evolution of the infection, the stability of the prosthesis and
the absence of poor prognostic factors, an evaluation was performed using the KLIC
scale ([Table 6]), the result of which was 2.
Table 6
|
Characteristics of the microorganism
|
Guest characteristics
|
|
Organism identified preoperatively
|
Good bone stock
|
|
Organism susceptible to antibiotic therapy
|
Good soft tissue condition (no fistulas, good skin coverage)
|
|
Immunocompetent
|
|
No sepsis
|
A surgical intervention was scheduled with debridement and polyethylene exchange,
and an intraoperative lavage with abundant saline was performed. Intraoperative cultures
isolated the Staphylococcus epidermidis sensitive to vancomycin. The patient received
intravenous vancomycin for six weeks, followed by oral rifampin and levofloxacin for
three months. The outcome was favorable, with normalization of inflammatory markers
and no signs of persistent infection.
Case 2
The second case involved an 81-year-old man with a history of hypertension and chronic
obstructive pulmonary disease (COPD) who had undergone total right knee replacement
for osteoarthritis of the knee. The patient presented five months after surgery with
progressively increasing pain in the operated knee and the appearance of a seropurulent
discharge. Medical history revealed a history of recurrent urinary tract infections
within the previous 4 weeks, leading to suspicion of hematogenous dissemination.
On examination, the patient presented marked edema and erythema around the surgical
wound, with purulent discharge. The patient was afebrile, although he reported general
malaise and progressive functional impairment of the joint.
Laboratory tests revealed elevated CRP at 155 mg/L, ESR at 72 mm/h, and leukocytosis
at 13,500/µL. Creatinine was 1.5 mg/dL, with an estimated glomerular filtration rate
of 48 ml/min. Joint aspiration revealed a leukocyte count of 35,000/µL, with 95% polymorphonuclear
cells, and Gram staining showed the presence of Gram-positive cocci. Radiography revealed
early signs of loosening of the tibial component ([Figure 2]).
Figure 2 AP and lateral X-rays of the patient in case 2 showing early signs of loosening of
the total knee prosthesis, with visible osteolysis in the medial tibial plateau and
a double contour image in the lateral plateau.
The CRIME80 assessment revealed a score of 6, so the risk of DAIR failure was high,
and it was decided to opt for a two-stage prosthetic revision.
Single-stage revision
Single-stage revision is an attractive option as it aims to resolve the infection
while avoiding a second surgery, thus achieving lower surgical morbidity and mortality,
faster functional recovery, and, consequently, an improvement in the patient's quality
of life. Furthermore, it significantly reduces healthcare costs and, therefore, total
healthcare expenditure.[18]
Another important advantage is the reduction in the duration of postoperative systemic
antibiotic treatment, which decreases both side effects and the risk of developing
antimicrobial resistance.[19]
However, single-stage revision does not apply to all patients, as there are specific
selection criteria. The Second International Consensus Meeting on Musculoskeletal
Infection, held in Philadelphia, established the following criteria[20]:
-
· Non-immunocompromised patient.
-
· Absence of systemic sepsis.
-
· Minimal bone loss and soft tissue defect allowing for primary wound closure.
-
· Identification of pathogens before surgery.
-
· Known susceptibility of isolated microorganisms.
-
Relative contraindications include severe soft tissue damage that prevents direct
closure, presence of an unresectable fistula along with the scar from the initial
intervention, joint infection with negative culture, inability to perform radical
debridement or apply local antimicrobial treatment, and lack of adequate bone stock
for fixation of the new implant ([Figure 4]).
Figure 3 Through the DAIR procedure, extensive debridement is performed, and the mobile components
are replaced, in this case, the polyethylene, without removing the remaining prosthesis
components.
Figure 4 Image of a fistula with three openings along the scar pathway of an infected hip
prosthesis. Its presence contraindicates a one-stage revision.
In addition to the selection criteria, the key steps for the success of this technique
include aggressive debridement of soft tissues, complete removal of the implants and
primary cement, as well as the use of antibiotic-loaded cement at the time of revision,
accompanied by a specific postoperative antibiotic therapy protocol. If these criteria
and steps are properly applied, the outcomes can be comparable to - or even better
than - those of two-stage exchange in preselected patients.[21]
Two-stage revision
In the remaining cases that do not fit any of the indications mentioned for the two
previous techniques, we should opt for the gold standard, which will involve removing
the components of the prosthesis, applying a spacer with antibiotics along with a
regimen of intravenous and oral antibiotic therapy, and in another surgical procedure,
implanting the new prosthesis.
Spacers
There are two main types of spacers: static, which prevents joint movement, and dynamic/articulated.
The primary purpose of both is to safely deliver adequate concentrations of antibiotics
over an extended period to the bone and surrounding soft tissues to eradicate the
infection ([Figure 5]).
Figure 5 Lateral knee and anteroposterior hip X-rays. Both images show two examples of static
or rigid cemented spacers: (a) Static spacer with intramedullary arthrodesis nail
that prevents knee flexion-extension. (b) Static hip spacer, a useful option for patients
lacking an adductor mechanism in the hip.
Dynamic spacers have certain advantages, such as better preservation of bone stock,
less soft tissue retraction, and less muscle atrophy, which contributes to a more
favorable functional recovery and facilitates reimplantation surgery ([Figure 6]). Furthermore, they have been observed to reduce hospital stays compared to static
spacers. Initially, non-articulating spacers were thought to have lower rates of dislocation
and fracture. However, current literature reports similar rates of these complications
for both types of spacers, and the latest international consensus tends to favor the
use of articulated spacers.[22]
[23]
Figure 6 Lateral knee and axial hip X-rays. Articulated spacers offer greater functionality
and shorter hospital stays: (a) Mobile knee spacers; continuous movement aids antibiotic
diffusion and preserves bone stock. (b) Articulated hip spacer in a case with multiple
revision surgeries and significant bone loss.
Currently, spacers can be classified into six major categories[24]:
-
· Intraoperatively made spacer, recreating the patient's anatomy or adapting to severe bone defects. They are inexpensive
and allow for customized antibiotic loading, but their manufacture is complex and
can cause irregularities in the joint surface. ([Figure 7])
-
· Silicone or aluminum molds, which allow for the manufacture of more congruent spacers and the customization
of the antibiotic load, in addition to facilitating the inclusion of femoral or tibial
stems in cases of significant bone defects. ([Figure 6a])
-
· Preformed spacers: offer a quick and easy option, although with the disadvantage of not being able
to customize the antibiotic load. ([Figure 6b])
-
· Prostalac: Hybrid spacers with plastic and metal components coated with antibiotic cement,
which improves function between surgical stages without compromising infection eradication.
-
· Spacer prosthesis: This uses a sterile prosthesis secured with antibiotic cement. In some studies,
up to 40% of patients treated with this technique do not require a second surgery.
([Figure 5a]).
-
· Custom-made spacers for massive defects, combining massive prostheses coated with antibiotic cement or
reconstruction nails.
Figure 7 AP knee X-ray showing a manually molded spacer. These spacers can be a useful alternative
to tailor antibiotics to the specific pathogen and cover large defects in cases of
bone stock loss. Clinical image provided by Dr. Almeida F.L.
In addition to improving joint function between surgical stages, antibiotic-loaded
cement spacers allow for intra-articular concentrations that exceed the minimum bactericidal
concentration, reducing the risk of antibiotic resistance without causing systemic
toxicity. To achieve this, the antibiotic used must meet certain criteria: it must
be available in sterile powder form, be thermostable and water-soluble, cause minimal
inflammatory or allergic reaction in the host, and reach an adequate concentration
in the bloodstream without systemic toxicity. The combination of aminoglycosides and
glycopeptides, such as gentamicin and vancomycin, is the most used due to their antibiotic
synergy and the thermal stability of vancomycin.
Interstage Period
Although it has traditionally been established that a definitive replacement of the
components should be delayed at around 6 weeks, the latest revisions are in favor
of using acute phase reactants to focus our treatment and not delay the second surgery
any longer than necessary ([Figure 8]).
Figure 8 Summary of management strategies for periprosthetic infection. Adapted from Li C.
et al.[23]
Thus, for patients who remain asymptomatic, whose PCR has remained negative or within
the threshold, and whose soft tissue status is adequate for further surgery, the second
approach would be indicated at that time. This new approach reduces unnecessary prolonged
hospital stays, prevents the loss of muscle and bone mass, lessens the adverse effects
of systemic antibiotic therapy, and allows the patient to rehabilitate more quickly.[25]
[26]
On the other hand, there is no evidence that we should leave a period without antibiotic
treatment, which is known as an "antibiotic holiday" before the definitive implantation
of our prosthesis.[27] The need for culture during reimplantation should not justify observing an antibiotic
holiday period, as the data derived from this practice are ineffective in predicting
procedural success and guiding the surgical plan. The duration of an antibiotic-free
period does not appear to significantly affect the rate of PJI after reimplantation.
However, many patients fail during the antibiotic-free period.
Proposed Management Algorithm
The algorithm presented in this paper proposes a structured strategy for the management
of periprosthetic infection, based on the time of symptom onset and specific clinical
factors. Its application facilitates decision-making between the main therapeutic
options: implant-retaining debridement (DAIR) or prosthetic replacement in one or
two stages.
The key criteria for each clinical scenario are described below, with examples illustrating
their application.
Periprosthetic Infection with Symptoms ≤4-6 weeks
In this group of patients, if the following criteria are met, the DAIR approach is
recommended:
-
· Absence of fistulas and healthy skin.
-
· Identification of the microorganism and confirmed sensitivity to antibiotics.
-
· Exclusion of infections with difficult pathogens (polymicrobial, fungal, or enterococcal).
-
· Stable implant with no signs of mobilization.
Clinical example:
A 67-year-old male patient with a knee prosthesis implanted 3 months ago presents
with pain, mild swelling, and intermittent fever for the past 3 weeks. Joint puncture
yields a positive culture for methicillin-sensitive Staphylococcus aureus (MSSA).
No fistulas or loosening are observed on the radiograph. In this case, the algorithm
indicates the patient is a candidate for DAIR.
If the above criteria are not met, DAIR is ruled out and a prosthetic replacement
is considered.
Periprosthetic infection with symptoms >4-6 weeks
In chronic infections, treatment requires a replacement of components, the modality
of which will depend on additional clinical factors.
One-stage revision
One-stage revision is considered if the following criteria are met:
-
· Microorganisms identified and adequately sensitive to antibiotics.
-
· Good bone stock.
-
· Good soft tissue condition (no fistulas, well-covered skin).
-
· Immunocompetent patient.
-
· Absence of sepsis.
Clinical example:
A 72-year-old woman with a hip replacement for 8 years developed an infection with
progressive symptoms over the past 3 months. Rifampicin-susceptible Staphylococcus
epidermidis was identified by arthrocentesis. There were no signs of fistulas or sepsis,
and bone stock was adequate. In this case, a single-stage bone replacement is a viable
option.
Two-stage revision
Two-stage revision is preferred in the following scenarios:
-
· Infection with microorganisms that are difficult to eradicate (polymicrobial, fungal,
enterococcal).
-
· Significant bone deficiency.
-
· Presence of fistulas or poor skin coverage.
-
· Immunocompromised or poorly maintained patient.
-
· Presence of sepsis.
Clinical example:
A 74-year-old male with a knee replacement performed 10 years earlier, with a fistula
draining purulent material and positive cultures for Enterococcus faecalis and Pseudomonas
aeruginosa. He presented with limited bone stock with cortical resorption. In this
case, the algorithm indicated the need for a two-stage replacement. Upon surgical
revision, abundant sloughing and synovial hypertrophy were observed, and the entire
periprosthetic tissue was widely infected ([Figure 9]). After this, it was decided to perform extensive lavage with radical debridement,
and the prosthesis was replaced with a preformed cement spacer ([Table 7]). After 6 weeks of antibiotic treatment (intravenous for the first two and oral
for the following 4), it was decided to apply a hinge-type prosthesis with a femoral
trabecular cone due to the lack of bone stock ([Figure 10] and [11]).
Figure 9 Intraoperative image of a patient requiring a two-stage revision due to knee prosthesis
infection. Numerous sloughs covering the knee prosthesis are observed, accompanied
by synovial hypertrophy and purulent drainage. Clinical image provided by Dr. López
R.
Figure 10 Sequence of X-rays illustrating the two-stage revision process in the same patient:
10a: Initial X-ray showing lateral tibial radiolucency and lytic bone loss in the
femur and tibia. 10b: Postoperative X-ray after the first stage with a preformed spacer
implant. 10c: X-ray after definitive surgery showing the final hinged prosthesis with
tibial and femoral stems. Clinical images provided by Dr. López R.
Figure 11
Conclusions
The management of periprosthetic infections continues to represent a complex clinical
challenge, given the variability in their diagnosis and treatment. However, the application
of systematic strategies, such as the use of risk stratification scales (e.g., KLIC
and CRIME80), allows for more precise guidance in the choice between DAIR and prosthetic
replacement in one or two stages. In clinical practice, it is recommended to adopt
standardized protocols that include close coordination between multidisciplinary teams
- with the participation of specialists in infectious diseases, microbiology, and,
when necessary, plastic and reconstructive surgery - to optimize the therapeutic approach.
Furthermore, it is essential to implement measures that facilitate early identification
of the microorganism and assessment of the implant's condition, which can significantly
improve treatment outcomes. In this context, it is suggested that new diagnostic technologies,
such as next-generation sequencing, be integrated to improve decision-making ([Table 8]).
Finally, the development of less invasive surgical techniques and the optimization
of antibiotic therapies—especially those targeting biofilm—are key areas for future
research. These advances could not only reduce morbidity, mortality, and associated
costs but also lay the groundwork for sustained improvements in the management of
periprosthetic infections.
Table 7
|
KLIC Criterion
|
Patient
|
Score
|
|
Chronic kidney failure (Kidney's disease)
|
1 points
|
NO
|
|
Cirrhosis (Liver)
|
1, 5 points
|
NO
|
|
I Index surgery (revision or post-fracture)
|
1,5 points
|
NO
|
|
C Cementation
|
2 points
|
SI
|
|
C CPR > 115mg/L
|
2 points
|
NO (40)
|
Table 8
|
Variable
|
Score
|
Patient
|
|
C Chronic obstructive pulmonary disease (COPD)
|
1
|
SI
|
|
CRP > 150 mg/L
|
1
|
SI (155)
|
|
R Rheumatoid arthritis
|
3
|
NO
|
|
I Index surgery (following fracture)
|
3
|
NO
|
|
M Male
|
1
|
SI
|
|
E Polyethylene exchange
|
-1
|
NO
|
|
> 80 years
|
2
|
SI
|